GENECHEM
GeneChem fund and the changing landscape of the genomics industry, the principals set out to raise their second focused fund, GeneChem Therapeutics Venture Fund L.P.. With committed capital of $136.5 million, the Therapeutics Fund's objectives were to invest within the genomics industry but specifically in companies developing therapeutics for proliferative disorders including cancer, infectious diseases, inflammation and diabetes.
GENECHEM
Industry:
Genetics
Founded:
1997-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS
Current Employees Featured
Fabienne Perreau
Fabienne Perreau Administrative Assistant @ GeneChem Administrative Assistant
Martial Lacroix
Martial Lacroix General Partner @ GeneChem General Partner
Inรจs Holzbaur
Inรจs Holzbaur General Partner @ GeneChem General Partner
John Clement
John Clement General Partner @ GeneChem General Partner
Patricia Laplante
Patricia Laplante Project Manager @ GeneChem Project Manager
Elizabeth Douville
Elizabeth Douville General Partner @ GeneChem General Partner
Maxime Pesant
Maxime Pesant Vice-President, Finance @ GeneChem Vice-President, Finance
Kevin McBride
Kevin McBride Project Manager @ GeneChem Project Manager
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2008-09-03 | Osprey Pharmaceuticals USA | GeneChem investment in Series A - Osprey Pharmaceuticals USA | 11 M USD |
2007-11-14 | Ambit Biosciences | GeneChem investment in Series D - Ambit Biosciences | 49.3 M USD |
2007-01-30 | Osprey Pharmaceuticals USA | GeneChem investment in Venture Round - Osprey Pharmaceuticals USA | 9 M USD |
2007-01-18 | Cytochroma | GeneChem investment in Series C - Cytochroma | 21 M CAD |
2006-12-01 | Xanthus Pharmaceuticals | GeneChem investment in Series B - Xanthus Pharmaceuticals | 25 M USD |
2005-05-12 | Ambit Biosciences | GeneChem investment in Series C - Ambit Biosciences | 31 M USD |
2004-04-27 | NewBiotics | GeneChem investment in Series E - NewBiotics | 4.57 M USD |
2003-12-12 | Xanthus Pharmaceuticals | GeneChem investment in Series B - Xanthus Pharmaceuticals | 30.8 M USD |
2003-07-03 | LymphoSign | GeneChem investment in Series A - LymphoSign | 5.9 M USD |
2002-12-09 | Idun Pharmaceuticals | GeneChem investment in Series A - Idun Pharmaceuticals | 22.8 M USD |